CLINICAL_TRIALS trial_result · 2018-06-27

Clinical Trial Update: A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) [Phase 3]

ENLIGHTEN-1, a Phase 3 trial of ALKS 3831 in adults with acute exacerbation of schizophrenia, has completed and posted its results.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Alkermes, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2018-06-27